Atsena Therapeutics expands its ATSN-201 trial for X-linked retinoschisis, a step toward the first gene therapy treatment.

Boehringer Ingelheim initiates THULITE study, exploring an oral treatment for diabetic macular edema, aimed to improve patient care and convenience.

Belite Bio completes enrollment in the pivotal PHOENIX trial, advancing Tinlarebant's potential to treat geographic atrophy.

At the 2025 Annual Meeting, I had the privilege of 1 I have been working on over the past year—exploring how retinal imaging might help detect early signs of Alzheimer disease (AD), especially in ...

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.

Breye Therapeutics advances danegaptide, a novel oral therapy for non-proliferative diabetic retinopathy, showing promise in early clinical trials.

PYC Therapeutics advances VP-001 for retinitis pigmentosa, securing FDA guidance for its upcoming registrational trial design and study parameters.

Ahead of the Clinical Trials at the Summit (CTS) meeting in Las Vegas, Nevada, Victor Gonzalez, MD, shared an overview of his presentation. Dr. Gonzalez is a trial investigator in the REMAIN follow-up ...

Modern Retina’s recent Case-Based Roundtable focused on next-generation treatments for retinal disease that provide advanced care for neovascular age-related macular degeneration (nAMD) and diabetic ...

Free diabetic retinopathy (DR) screenings begin this week through a collaboration between Avant Technologies, Ainnova Tech and Grupo Dökka, Fischel Pharmacies and La Bomba Pharmacies, according to a ...

Christine Kay, MD, presented interim 1-year data from a phase 1/2 study of an investigational gene therapy (OPGx-LCA5; Opus Genetics) for LCA5-related Leber congenital amaurosis at the Clinical Trials ...